AIMT - Aimmune Therapeutics, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
22.77
+0.39 (+1.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close22.38
Open22.67
Bid0.00 x 800
Ask0.00 x 1300
Day's range22.41 - 22.94
52-week range16.95 - 36.12
Volume1,098,595
Avg. volume840,276
Market cap1.427B
Beta (3Y monthly)0.49
PE ratio (TTM)N/A
EPS (TTM)-3.73
Earnings date8 Aug 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est47.70
Trade prices are not sourced from all markets
  • Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
    Zacks

    Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

    Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.

  • Aimmune's Peanut Allergy Drug Gets FDA Committee's Support
    Zacks

    Aimmune's Peanut Allergy Drug Gets FDA Committee's Support

    Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.

  • Business Wire

    FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use of AR101 (proposed trade name PALFORZIA™) in children and teens with peanut allergy. PALFORZIA is a complex, biologic oral immunotherapy (OIT) candidate designed to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanut in patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy.

  • Business Wire

    Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration (FDA) Allergenic Products Advisory Committee (APAC) is holding a meeting today from 8:30 a.m. to 4:30 p.m. ET to discuss whether efficacy and safety data support licensure of PALFORZIA™ as a treatment to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanut in patients 4 through 17 years of age with a confirmed diagnosis of peanut allergy. The briefing materials can be found here on the FDA website.

  • Peanut Allergy Drug Faces Next Test at Key FDA Panel Meeting
    Bloomberg

    Peanut Allergy Drug Faces Next Test at Key FDA Panel Meeting

    (Bloomberg) -- Aimmune Therapeutics Inc.’s winding road to get its first allergy treatment approved by U.S. regulators faces its next turn when a panel of advisers to the Food and Drug Administration meets later this week.The advisory committee’s discussion and recommendation on Sept. 13 may guide investors seeking details about the potential commercial success of a product designed to protect patients with peanut allergies.Bullish analysts expect the panel to back the drug, AR101, and its ground-breaking potential. They are looking for such an endorsement to lift shares, which have shed more than 30% of their value since a November high. At recent levels, some Wall Street price targets project Aimmune could double or triple in price over the next 12 months.Among skeptics is Stifel’s Derek Archila, who is hesitant to advise clients to buy shares before the “binary catalyst” of the advisory committee. Archila in a research note wrote that he expects the panel to focus on the safety of AR101, which is derived from peanut flour. A negative vote could cut the value of Aimmune’s shares in half, while a positive review from the advisers may prompt a 30% climb.“The FDA is really going to be charged with whether it can get comfortable with the longer-term safety,” he said in a telephone interview. “The crux of the AdComm will be if there is a need for longer-term safety data to really understand if you’re putting these kids at undue risk by giving them the allergen they’re allergic to.”Jayson Dallas, chief executive officer of Aimmune, said in an interview at Bloomberg’s New York headquarters: “There almost surely will be discussion around the macro-level risk/benefit, but then maybe digging into some patient populations.”A successful panel meeting followed by U.S. clearance over the coming months would make Aimmune’s AR101 the first desensitization therapy approved for an allergy that affects more than 1.6 million kids and teens and can produce potentially life-threatening reactions.When thinking about the company’s sales potential, Dallas mentioned GW Pharmaceuticals Plc’s cannabinoid-based drug Epidiolex as a comparison.“They were the only player in town, with a high unmet need and clear pent-up demand,” but sales didn’t really pick up until insurance coverage started to take hold, Dallas said. Epidiolex brought in $68.4 million of U.S. sales for the three months ended June 30, compared with $33.5 million for the prior quarter.While U.S. regulators review Aimmune’s treatment, a nonprofit research group has already weighed in. The Institute for Clinical and Economic Review (ICER) in a July report said there isn’t enough evidence to show that the “long-term benefits of desensitization outweigh short-term risks.”The company, along with analysts like Piper Jaffray’s Christopher Raymond, criticized the report at the time. Raymond called it “yet another example of ICER’s inherent bias against any novel therapy.” Aimmune said “ICER fails to incorporate available data on both long-term outcomes and quality of life.”If AR101 does win approval, analysts project annual sales could exceed $1.2 billion by 2024, data compiled by Bloomberg show. RBC Capital Markets’ Kennen MacKay wrote in an August note that the majority of U.S. allergists are waiting for an FDA-approved therapy to offer patients, which could push sales toward $1.9 billion worldwide.Another aspect that could affect the uptake of AR101 is whether the FDA will require a safety program to help ensure the benefits outweigh its risks. The company’s CEO said such a plan would “not be a big deal” because Aimmune is planning to assess patients over longer periods of time and look for larger groups of patients.An approval would likely come with a “black box” warning, the FDA’s most serious caution, according to both Aimmune’s Dallas and Stifel’s Archila, though this would be in-line with other allergy medicines.If Aimmune can find market success fighting peanut allergy, that might bode well for its experimental approaches to egg and tree-nut allergies. The Brisbane, California-based company enrolled the first patient in a mid-stage egg-allergy study at the end of August.“Validation of the platform and its concept will speed up our egg program and create more excitement for the egg program and our tree nut program,” Dallas said.Options in Aimmune set to expire on Sept. 20 are expecting a 36% move in shares over the next two weeks. Traders appear to be hedging more than making bullish bets, with put options outweighing calls. Investors are also preparing for an outsized move with implied volatility sitting at about 259%, well above a three-month average of 41%.This month’s FDA allergy panel may have implications for DBV Technologies SA, which is developing a patch for peanut-allergic children ages four to 11. DBV last month submitted its application for Viaskin Peanut after the FDA had previously requested additional data.While the FDA typically heeds the advice of its panels, the agency isn’t obligated to follow it. Karyopharm Therapeutics Inc.’s blood cancer drug Xpovio is a recent reminder. Regulators cleared the drug for market four months after a panel voted that a decision should be delayed for more data.\--With assistance from Gregory Calderone.To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Jeremy R. CookeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • 3 Biotech Stocks That Could Soar This Week
    Motley Fool

    3 Biotech Stocks That Could Soar This Week

    Investors better get ready for a busy week ahead.

  • Business Wire

    Aimmune to Participate in Three Investor Conferences in September

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune execut

  • Implied Volatility Surging for Aimmune (AIMT) Stock Options
    Zacks

    Implied Volatility Surging for Aimmune (AIMT) Stock Options

    Investors need to pay close attention to Aimmune (AIMT) stock based on the movements in the options market lately.

  • Business Wire

    Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of egg allergy. AR201, an investigational biological drug for use in oral immunotherapy for egg allergy, is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform. Egg allergy is a common and serious condition that disproportionately affects children and can be associated with severe hypersensitivity reactions, including life-threatening anaphylaxis.

  • 3 Top Biotech Stocks to Buy in August
    Motley Fool

    3 Top Biotech Stocks to Buy in August

    In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.

  • Aimmune Therapeutics, Inc. (AIMT) Q2 2019 Earnings Call Transcript
    Motley Fool

    Aimmune Therapeutics, Inc. (AIMT) Q2 2019 Earnings Call Transcript

    AIMT earnings call for the period ending June 30, 2019.

  • Business Wire

    Aimmune to Present at the Wedbush PacGrow Healthcare Conference

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019, at 3:05 p.m.

  • Aimmune Down on Negative ICER Review on Allergy Candidate
    Zacks

    Aimmune Down on Negative ICER Review on Allergy Candidate

    Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.

  • Here's Why Aimmune Therapeutics Fell 7% Today
    Motley Fool

    Here's Why Aimmune Therapeutics Fell 7% Today

    The Institute for Clinical and Economic Review questions the short-term risks of the biotech's drug.

  • Business Wire

    Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for AR101, an investigational biologic oral immunotherapy to reduce the frequency and severity of allergic reactions following exposure to peanuts in children and adolescents ages ...

  • Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Is Expected To Breakeven
    Simply Wall St.

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Is Expected To Breakeven

    Aimmune Therapeutics, Inc.'s (NASDAQ:AIMT): Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company...

  • What Makes Aimmune Therapeutics (AIMT) a New Buy Stock
    Zacks

    What Makes Aimmune Therapeutics (AIMT) a New Buy Stock

    Aimmune Therapeutics (AIMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Business Wire

    Aimmune to Present at the JMP Securities Life Sciences Conference

    Aimmune Therapeutics, Inc.  , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 2:30 p.m.

  • Business Wire

    Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at the Institute for Clinical and Economic Review’s (ICER) Public Meeting reviewing the effectiveness and value of treatments for peanut allergy, to be held today in Oakland, California. Aimmune is developing AR101, an investigational biologic drug for use in oral immunotherapy as a treatment to reduce the frequency and severity of allergic reactions following exposure to peanuts. Using only clinical data from the landmark Phase 3 PALISADE trial, ICER found AR101 to be cost-effective well-below ICER’s traditional threshold of $100,000-$150,000 per QALY.

  • Business Wire

    Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference

    Aimmune Therapeutics, Inc.  , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Sachs 40th Annual Healthcare Conference on Wednesday, June 12, 2019 at 9:20 a.m.

  • Business Wire

    Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy

    Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced new data from two studies that assessed the psychosocial burden of living with peanut allergy. Results from APPEAL 2, the first European multi-country qualitative evaluation of the impact of living with peanut allergy, found that living in fear of a potentially fatal reaction to peanuts significantly impacts the quality of life of individuals with peanut allergy and their families. AR101 is an investigational biologic drug for use in oral immunotherapy as a treatment to reduce the frequency and severity of allergic reactions following exposure to peanuts.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more